BofA, Leerink are the joint bookrunners; Cowen and Wedbush will assist
By Devika Patel
Knoxville, Tenn., July 17 – Roka BioScience, Inc. said it priced its $60 million initial public sale of stock with a $9 million greenshoe. The deal was announced May 21.
The company will sell 5 million common shares at $12.00 per share.
BofA Merrill Lynch and Leerink Partners are the joint bookrunners.
Settlement is expected July 22.
Proceeds will be used for research and development.
The molecular diagnostics company is based in Warren, N.J. The company intends to list its common stock on the Nasdaq under the symbol “ROKA.”
| Issuer: | Roka BioScience, Inc.
|
| Issue: | Common stock
|
| Amount: | $60 million
|
| Greenshoe: | $9 million
|
| Shares: | 5 million
|
| Price: | $12.00
|
| Warrants: | No
|
| Bookrunners: | BofA Merrill Lynch and Leerink Partners
|
| Co-managers: | Cowen and Co. and Wedbush PacGrow Life Sciences
|
| Announcement date: | May 21
|
| Pricing date: | July 17
|
| Settlement date: | July 22
|
| Stock exchange: | Nasdaq: ROKA
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
